Subscribe to news

Two Moscow Exchange Indices to Include HSCI Shares from December 17, 2013

Moscow – 4 December 2013 OJSC HSCI – The Human Stem Cells Institute (“HSCI”, MOEX: ISKJ), one of Russia’s leading biotech companies specializing in cell-based, gene and post-genome technologies, today announced its ordinary shares to be included in the Broad Market Index and the Second-Tier Index of the Moscow Exchange.

HSCI ordinary shares will be added to the forenamed indices for the first time.

According to Moscow Exchange release, revised lists for the Broad Market Index and the Second-Tier Index are effective starting December 17, 2013 through March 17, 2014.

As a rule, these lists are reconsidered four times per year. As of today, HSCI ordinary shares are also included in the MICEX-Innovation (MICEX INNOV) - the first Index of innovative companies in Russia. Launch of this Index - an indicator of MICEX Innovation and Investment Market (now - iIM MOEX) - was held on July 13, 2011. HSCI shares have been weighted in the MICEX-Innovation Index from the day of its launch.

Therefore, starting December 17, 2013, HSCI ordinary shares are to be employed in the calculation of three Moscow Exchange indices: the Broad Market Index, the Second-Tier Index and the MICEX-Innovation Index.

The Moscow Exchange Broad Market Index includes the top 100 shares selected by the criteria of liquidity, capitalization and shares that are in free-float. The Index’s list of securities is used as the basis for the constituent list of other indices of the Moscow Stock Exchange.

The Moscow Exchange Second-Tier Index is formed on the basis of the Broad Market Index and shares that are not included in the Moscow Exchange Indices (MICEX Index and RTS Index). Second-tier index has a united approach to the index calculation and the eligibility of shares to be included in index portfolio based upon using different criteria of liquidity to the different capitalization groups.

Full Version of the Press Release (226 kb)

04 December 2013